{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:28:30Z","timestamp":1768566510634,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jaclp.2024.12.003","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T08:50:05Z","timestamp":1736067005000},"page":"139-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bromocriptine for Residual Catatonia Following Neuroleptic Malignant Syndrome: Illustrative Case Report and Systematic Review"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-1041","authenticated-orcid":false,"given":"Bernard","family":"Sarmiento","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Gunther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5979-4325","authenticated-orcid":false,"given":"Alexis","family":"Cohen-Oram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6236-8775","authenticated-orcid":false,"given":"Shixie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaclp.2024.12.003_bib1","first-page":"870","article-title":"Neuroleptic malignant syndrome","volume":"164","author":"Strawn","year":"2007","journal-title":"Aust J Pharm"},{"key":"10.1016\/j.jaclp.2024.12.003_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/acps.13359","article-title":"A\u00a0systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome","volume":"144","author":"Guinart","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jaclp.2024.12.003_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12028-015-0162-5","article-title":"Neuroleptic malignant syndrome: complications, outcomes, and mortality","volume":"24","author":"Modi","year":"2016","journal-title":"Neurocritical Care"},{"key":"10.1016\/j.jaclp.2024.12.003_bib4","first-page":"185","article-title":"Neuroleptic malignant syndrome","volume":"77","author":"Caroff","year":"1993","journal-title":"Med Clin"},{"key":"10.1016\/j.jaclp.2024.12.003_bib5","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/1060028016657553","article-title":"Neuroleptic malignant syndrome","volume":"50","author":"Pileggi","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaclp.2024.12.003_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1941875210386491","article-title":"Neuroleptic malignant syndrome","volume":"1","author":"Berman","year":"2011","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.jaclp.2024.12.003_bib7","series-title":"StatPearls","article-title":"Neuroleptic malignant syndrome","author":"Simon","year":"2023"},{"key":"10.1016\/j.jaclp.2024.12.003_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/ajp.156.2.169","article-title":"Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome","volume":"156","author":"Gurrera","year":"1999","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1592\/phco.28.4.530","article-title":"Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations","volume":"28","author":"Picard","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaclp.2024.12.003_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e3181c9bfe6","article-title":"Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome","volume":"30","author":"Lee","year":"2010","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2024.12.003_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/S1092852900013365","article-title":"The universal field hypothesis of catatonia and neuroleptic malignant syndrome","volume":"5","author":"Carroll","year":"2000","journal-title":"CNS Spectr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00004714-199706000-00026","article-title":"The nondichotomy between lethal catatonia and neuroleptic malignant syndrome","volume":"17","author":"Carroll","year":"1997","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2024.12.003_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5498\/wjp.v6.i4.391","article-title":"Catatonia: our current understanding of its diagnosis, treatment and pathophysiology","volume":"6","author":"Rasmussen","year":"2016","journal-title":"World J Psychiatr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1017\/S1092852900013407","article-title":"Is lorazepam a treatment for neuroleptic malignant syndrome?","volume":"5","author":"Francis","year":"2000","journal-title":"CNS Spectr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib16","first-page":"58","article-title":"An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome","volume":"5","author":"White","year":"2000","journal-title":"CNS\u00a0Spectr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200004000-00021","article-title":"Residual catatonic state following neuroleptic malignant syndrome","volume":"20","author":"Caroff","year":"2000","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2024.12.003_bib18","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jaclp.2024.12.003_bib19","first-page":"302","article-title":"Detection and management of the neuroleptic malignant syndrome","volume":"3","author":"Bond","year":"1984","journal-title":"Clin Pharm"},{"key":"10.1016\/j.jaclp.2024.12.003_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5144\/0256-4947.1988.122","article-title":"The neuroleptic malignant syndrome","volume":"8","author":"Obeid","year":"1988","journal-title":"Ann Saudi Med"},{"key":"10.1016\/j.jaclp.2024.12.003_bib21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00004714-199510000-00010","article-title":"Clozapine-induced neuroleptic malignant syndrome: review and report of new cases","volume":"15","author":"Sachdev","year":"1995","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2024.12.003_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001752","article-title":"A\u00a0case report of catatonia and neuroleptic malignant syndrome with multiple treatment modalities: short communication and literature review","volume":"94","author":"Chiou","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jaclp.2024.12.003_bib23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.20344\/amp.13019","article-title":"Diagnosis and treatment of neuroleptic malignant syndrome in the intensive care unit: a case report","volume":"34","author":"Maia","year":"2021","journal-title":"Acta Med Port"},{"key":"10.1016\/j.jaclp.2024.12.003_bib24","first-page":"1","article-title":"Malignant catatonia requiring high dose bromocriptine: case report","volume":"5","author":"Meresh","year":"2021","journal-title":"OBM Neurobiology"},{"key":"10.1016\/j.jaclp.2024.12.003_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/NMD.0b013e31827ab24b","article-title":"Catatonia and neuroleptic malignant syndrome: two disorders on a same spectrum? Four case reports","volume":"201","author":"Luchini","year":"2013","journal-title":"J\u00a0Nerv Ment Dis"},{"key":"10.1016\/j.jaclp.2024.12.003_bib26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/0004867419847758","article-title":"Electroconvulsive therapy for catatonia secondary to neuroleptic malignant syndrome in a patient with multiple sclerosis","volume":"53","author":"Harley","year":"2019","journal-title":"Aust N Z J Psychiatr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fpsyt.2014.00181","article-title":"A\u00a0clinical review of the treatment of catatonia","volume":"5","author":"Sienaert","year":"2014","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2023.03.013","article-title":"Molecular and immunological origins of catatonia","volume":"263","author":"Beach","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaclp.2024.12.003_bib29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.schres.2022.11.002","article-title":"Brain mechanisms underlying catatonia: a systematic review","volume":"263","author":"Cattarinussi","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaclp.2024.12.003_bib30","first-page":"272","article-title":"Going back to kahlbaum\u2019s psychomotor (and GABAergic) origins: is catatonia more than just a motor and dopaminergic syndrome?","volume":"46","author":"Hirjak","year":"2020","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaclp.2024.12.003_bib31","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/1440-1681.13678","article-title":"Bromocriptine therapy: review of mechanism of action, safety and tolerability","volume":"49","author":"Naz","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jaclp.2024.12.003_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hup.470070310","article-title":"Treatment of neuroleptic malignant syndrome with levodopa","volume":"7","author":"Otani","year":"1992","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jaclp.2024.12.003_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0033-3182(10)70709-X","article-title":"Neuroleptic malignant syndrome: further lessons from a case report","volume":"51","author":"Casamassima","year":"2010","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jaclp.2024.12.003_bib34","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/syn.20453","article-title":"Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors","volume":"61","author":"Seeman","year":"2007","journal-title":"Synapse"},{"key":"10.1016\/j.jaclp.2024.12.003_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1474-4422(22)00119-3","article-title":"The use of amantadine in catatonia","volume":"21","author":"Rengasamy","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaclp.2024.12.003_bib36","first-page":"378","article-title":"Specific treatment of the neuroleptic malignant syndrome","volume":"44","author":"Caroff","year":"1998","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0010-440X(00)90135-4","article-title":"Catatonic signs in neuroleptic malignant syndrome","volume":"41","author":"Koch","year":"2000","journal-title":"Compr Psychiatr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1600-0447.1988.tb06355.x","article-title":"Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam","volume":"78","author":"Kontaxakis","year":"1988","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jaclp.2024.12.003_bib39","series-title":"StatPearls","article-title":"Catatonia","author":"Burrow","year":"2023"},{"key":"10.1016\/j.jaclp.2024.12.003_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-3223(95)00552-8","article-title":"Neuroleptic malignant syndrome and catatonia: one entity or two?","volume":"39","author":"Fink","year":"1996","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib41","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00702-002-0762-z","article-title":"Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology","volume":"109","author":"Northoff","year":"2002","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.jaclp.2024.12.003_bib42","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.17r02185","article-title":"Neuroleptic malignant syndrome: diagnosis and management","volume":"20","author":"Ware","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.jaclp.2024.12.003_bib43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0006-8993(94)90821-4","article-title":"Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism","volume":"662","author":"Mizoguchi","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.jaclp.2024.12.003_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/j.1875-9114.1986.tb03475.x","article-title":"Neuroleptic-induced catatonia after abrupt withdrawal of amantadine during neuroleptic therapy","volume":"6","author":"Brown","year":"1986","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaclp.2024.12.003_bib45","first-page":"347","article-title":"Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues","volume":"56","author":"Rosebush","year":"1995","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaclp.2024.12.003_bib46","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0006-3223(97)00187-X","article-title":"Neuroleptic malignant syndrome with gangliosidosis type II","volume":"41","author":"Manor","year":"1997","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jaclp.2024.12.003_bib47","article-title":"Late onset tay-sachs disease presenting as a brief psychotic disorder with catatonia: a case report and review of the literature","volume":"15","author":"Saleh","year":"2012","journal-title":"Jefferson Journal of Psychiatry"},{"key":"10.1016\/j.jaclp.2024.12.003_bib48","article-title":"Catatonia in autism spectrum disorders: a systematic review and meta-analysis","volume":"65","author":"Vaquerizo-Serrano","year":"2021","journal-title":"Eur Psychiatry"}],"container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296024001381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296024001381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T20:59:31Z","timestamp":1746219571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667296024001381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2667296024001381"],"URL":"https:\/\/doi.org\/10.1016\/j.jaclp.2024.12.003","relation":{},"ISSN":["2667-2960"],"issn-type":[{"value":"2667-2960","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bromocriptine for Residual Catatonia Following Neuroleptic Malignant Syndrome: Illustrative Case Report and Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Academy of Consultation-Liaison Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaclp.2024.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}